STUDboardsPlay · Research · Self · Fit · Money · Learn · Study · Plan · Token STUDtokenOptional

STUDresearch · Non-peptide

PP405

Also known as

PP-405 · PP 405 · Suvomipic · JXL069 · JXL-069 · Pelage PP405 · PP405-3HP · MPC inhibitor hair gel

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗
Non-peptide Lots of talk Local Topical Skin, hair & tissue remodeling

Local — a scalp gel. Not a whole-body hormone.

What people say PP405 is Pelage’s investigational 0.05% topical MPC-inhibitor gel for androgenetic alopecia. A reviewed secondary comparison links JXL069 to the proposed INN suvomipic; WHO’s entry names neither JXL069 nor PP405. A public primary source completing the PP405 active-substance link was not located. Doses people talk about
Phase 2a gel0.05% topical once daily

Pelage’s controlled gel for 28 days in adults with androgenetic alopecia; participants were followed through week 12.

The Phase 2a amount and schedule describe Pelage’s controlled investigational product, not a retail label or a DIY formulation target.

Half-life & effect duration

Half-life in the body
  • Topical PP405No settled systemic estimate
Felt duration people report
  • Early outside accountNo change, then better growth of existing hair
  • Related-product accountsRegrowth claims or no response; these involve JXL069 / 3HP rather than verified PP405
Timing context & sources
How it may feel Community evidence is mixed and product-dependent. Two early JXL069 users reported no change; one later described better existing-hair growth without new hair. A reportedly tested raw-JXL069 group reported no meaningful result after 12 weeks, and that author also found no meaningful 3HP result. A different 3HP user described persistent shedding and apparent regrowth while continuing finasteride/minoxidil. None authenticates Pelage’s clinical gel.
Cycles people discuss The randomized Phase 2a block used 28 days of daily topical treatment followed by observation through week 12. That trial clock is not a public long-term maintenance schedule. Timing Existing community notes describe once-daily scalp use, often in the evening around morning minoxidil, and allowing layers to dry. These are reported habits, not validated timing or formulation equivalence. Stacks Minoxidil and finasteride are common concurrent therapies in community reports. That may be mechanistically complementary, but it prevents clean attribution and no PP405 combination trial was located. Access talk Anyone shipping “PP405” from a peptide shop is selling a research analog or an ester. Watch for Short trial: 28 days of drug. Long-term scalp/systemic table does not exist in public.
Related
MinoxidilFinasterideGT20029RU-58841Pyrilutamide

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

A systemic PP405 elimination half-life was not established in the reviewed public results.

The sponsor reported no PP405 detected in blood after controlled topical use and described that as no systemic absorption.

A nondetectable systemic signal under the study assay does not supply an elimination half-life and cannot be transferred to outside formulations.

Felt duration people report

No dependable single-application felt duration is established for PP405.

Clinical observation followed a 28-day block through week 12. Outside reports include early no change followed by better existing-hair growth without new hair, a 12-week JXL069 nonresponse whose author also reported 3HP nonresponse, and a different 3HP account of shedding plus apparent regrowth with ongoing finasteride/minoxidil.

Hair-cycle outcomes follow repeated treatment; outside products, vehicles, identity, photography and concurrent therapies differ from Pelage’s trial gel.

  • Pelage Pharmaceuticals Announces Positive Phase 2a Clinical Trial Results for PP405 (opens in a new tab)Trial design and sponsor-reported PK lines 34–44, especially once-daily four-week treatment, 12-week follow-up and no detected blood absorption at lines 38–40.Sponsor press release with topline and subgroup results, not a peer-reviewed full dataset; no numerical assay limit, raw PK table, long-term maintenance result or JXL069/suvomipic identity statement.
  • PP405 (JXL069) Is Confirmed: Here’s Everything I’ve Learned After a Year of Testing (opens in a new tab)OrneryRatio7313 same-author opening lines 17–44: 12-week raw-JXL069 use, asserted testing and group vehicle differences, no meaningful result, then the same author’s no-meaningful-result 3HP paragraph at lines 41–44.Self-report; third-party testing and group methods are asserted rather than independently audited here, vehicles varied, and the post overstates the still-unconfirmed link from JXL069/suvomipic to PP405.
  • Those using JXL069 (opens in a new tab)Day-5/day-11 reports lines 17–64; ChoiYoungSul later existing-hair improvement without new growth at lines 83–89; separate concomitant-dutasteride context through lines 151.Very early uncontrolled self-reports using an outside solution; identities, concentration, vehicle, photography and concurrent treatments are not standardized.
  • Week 11 Update Jxl069-3hp (pp405 replica) (opens in a new tab)Original post lines 17–23; ongoing finasteride/minoxidil confirmation lines 92–110; mixed week-five and week-eleven reports lines 133–166.Different ester product described as a replica, no authenticated equivalence to clinical PP405, ongoing finasteride/minoxidil, uncontrolled photographs and competing no-progress reports.

Other context in this card

  • Is Suvomipic (JXL069) Pelage’s PP405? (opens in a new tab)Evidence boundary lines 46–75, trial-registry distinction lines 153–176 and formulation distinction lines 220–247.Independent secondary evidence review. It establishes the published JXL069/suvomipic identifier match from cited primary records but explicitly finds no public primary source completing the PP405 identity link.
  • WHO Drug Information Vol. 40 No. 2: Proposed INN List 135 — suvomipic (opens in a new tab)PDF page 223 / printed page 661, suvomipic entry: chemical name, MPC inhibitor classification, formula C20H11F6N3O2 and CAS 2260696-63-5. Actual PDF text read in memory after direct HTTP 200 retrieval.Proposed INN chemical-identity entry; it does not name JXL069, PP405, Pelage or a clinical formulation. It cannot authenticate outside products or by itself complete the PP405 active-substance link. No structure-image interpretation is claimed.

What people say 5

  • DIY JXL069 albums: A few HairlossResearch/tressless users who mixed verified JXL069 reported little or nothing at 12 weeks — and said most shops were selling ester “3HP” versions instead. anecdote
  • What talk does not prove: A 2027 OTC minoxidil-killer. Phase 3 was still the 2026 waiting room. forum
  • Phase 2a density headline: After 4 weeks of gel and follow-up to week 8, 31% of men with more advanced loss had >20% density increase vs 0% on placebo — small study, short dose. trial
  • Terminal vs vellus: Company/conference talk that treated units grew terminal hair while placebo grew vellus. That is the 2026 slide people argue about. trial
  • No systemic absorption claim: Trial safety story is local gel, PK below meaningful blood levels. trial

Doses people talk about 4

  • PP405-3HP shop lotions: Marketed as a prodrug ester. Several testers said that version did nothing. forum
  • DIY JXL069: Users mixed raw powder into a leave-on; concentrations are n=1, not a label. anecdote
  • Framing: Trial gel percent and DIY milligrams — not a sold drug. forum
  • Trial gel: ~0.05% once daily for 28 days in Phase 2a. trial

How it may feel 4

  • Early community reports: Legacy DIY accounts describe vehicle feel, early hair-quality changes or nothing. Two JXL069 posters initially reported no change at days 5 and 11; the day-11 author later said existing hair seemed to grow better without new growth. One 12-week raw-JXL069 group account, which asserted third-party testing, reported no meaningful result; that author also reported no meaningful result from 3HP. A different 3HP user described persistent shedding and apparent regrowth while continuing finasteride and minoxidil. These products and vehicles are not authenticated as Pelage’s gel. anecdote
  • Month 3 DIY: People who ran authentic-looking JXL069 often posted “no meaningful change” and quit. anecdote
  • Stop: No 5-AR washout. If the bottle was an ester, you never ran the trial molecule. forum
  • Week 8 (trial clock): The density screenshot is four weeks after a 28-day dose, not a 12-month minoxidil album. trial

Around the dose 3

  • Clock: Once-daily scalp, usually evening so it is not fighting morning min foam. forum
  • Layering: People who already run min/fin keep those and treat PP405 as a third mechanism — wait to dry. forum
  • Not a pin. forum

Cycles people discuss 3

  • Stay-on lore: Hair people treat anything that works like minoxidil — stay on — but there is no public 12-month PP405 maintenance chart. forum
  • Trial block: 28 days on, then watch. trial
  • Open-label extension: Company described a longer safety follow-on; full dataset was still being promised to a 2026 meeting. trial

Timing 3

  • Why results lagged the dose: Density talk at week 8 after stopping at week 4 is the “follicle cycle, not a stimulant” argument. forum
  • Esters vs parent: 3HP talk is chemistry-board, not Pelage’s gel. forum
  • Local PK: Company line is the gel does not show meaningful systemic levels. trial

More on what it is 6

  • What most people mean: The “wake the dead follicles up” topical — not another DHT blocker. forum
  • Also called: WHO Proposed INN List 135 lists suvomipic with the chemical identity associated with JXL069 in the reviewed secondary comparison. The WHO entry does not name JXL069 or PP405. No public primary source reviewed here directly completes the PP405 active-substance link, and none authenticates outside products as Pelage’s clinical gel. forumtrial
  • Why people search it: Phase 2a headline (31% of more-advanced men >20% density jump at week 8 vs 0% placebo) plus a gray-market circus of “PP405” bottles that are not Pelage’s gel. forumtrial
  • Mechanism talk: Dormant follicle stem cells are still there; the pitch is flipping their energy state so they re-enter growth. Complementary to minoxidil/fin on paper. trialforum
  • Not: Not minoxidil, not finasteride, not GT20029, not stem-cell injections, not a peptide. forum
  • What it is: Pelage Pharmaceuticals (UCLA spinout) small-molecule MPC (mitochondrial pyruvate carrier) inhibitor, applied as a ~0.05% gel once daily in trials. Not a peptide. Not FDA-approved. trial

Stacks 4

  • + Minoxidil: Complementary-mechanism pitch. forum
  • + Finasteride / dutasteride: Keep the DHT block, add a follicle-wake story. forum
  • + GT20029: 2026 “new min + new fin” fantasy. No combo trial. forum
  • + AHK-Cu / GHK-Cu: Some DIY mixers add copper peptides to the same dropper. Attribution dies. anecdote

Access talk 3

  • Anyone shipping “PP405” from a peptide shop is selling a research analog or an ester. forum
  • JXL069 ≠ a verified Pelage batch even when the scaffold matches on paper. forum
  • Not for sale as the real drug. Phase 3 talk in 2026. trial

Storage notes 3

  • Raw JXL069 is mixed by users; light/air/ester choice is the whole identity fight. forum
  • Shop “PP405” lotions are not the trial gel. forum
  • Pelage product is a finished gel, not a peptide vial. trial

Watch for 5

  • Identity is the side effect. Most bottles labeled PP405 in 2026 were not Pelage’s gel. forum
  • Vehicle irritation possible like any leave-on. forum
  • Women: Company said the mechanism should apply; public diaries are mostly male AGA. forum
  • Short trial: 28 days of drug. Long-term scalp/systemic table does not exist in public. trial
  • Not stem cells. It is a metabolic topical, not an injection of cells. trial

Updated: 2026-09-01

Evidence mix Mostly community / anecdote tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.
↑ Back to top

All STUDresearch topics →